Compare Gitlab Inc (GTLB) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gitlab Inc vs Twist Bioscience Corp — how do they compare? Gitlab Inc trades at $31.76 (market cap $5.54B), while Twist Bioscience Corp trades at $90.03 (market cap $5.76B). The key difference: Gitlab Inc and Twist Bioscience Corp are close in size by market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Gitlab Inc nearer its low. Which is the better fit depends on your goals.
| GTLB | TWST | |
|---|---|---|
Market Cap | $5.54B | $5.76B |
Sector | Technology | Health |
52-Week High | $51.04 | $102.88 |
52-Week Low | $19.42 | $24.16 |
Enterprise Value | $4.29B | $5.69B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GitLab trades at $31.50, down 4.49% today, with a bullish technical signal from moving averages but mixed oscillators. Revenue grew to $759.25M in 2025, though net income remained negative at -$6.33M. Recent earnings beats and a strategic position in AI-driven DevSecOps, including a fourth consecutive Gartner Magic Quadrant leadership recognition (Business Wire, 2026-06-17), highlight growth potential despite profitability challenges.
The outlook balances strong revenue growth and market position against high valuation multiples and persistent losses. Analyst consensus targets $32.50, suggesting modest upside, but risks include execution on profitability and competitive pressures in the software sector. Cash flow trends show improvement projected for 2026, yet investor caution is warranted given the elevated P/E ratio of 521.22.
Twist Bioscience (TWST) trades at $90.33, down 2.46% on the day, with a bullish technical outlook despite recent earnings misses. The company shows strong revenue growth from $204M in 2022 to $377M in 2025, though it remains unprofitable with a -19.85% net margin. Analyst sentiment is positive with 11 buy ratings and a $91.63 consensus target, while recent news highlights AI collaborations and upcoming Q3 earnings.
TWST presents a growth story with improving margins and AI-driven demand, but profitability concerns and consistent cash burn pose risks. The stock trades near analyst targets, suggesting limited near-term upside without earnings acceleration. Key catalysts include Q3 results on August 3, 2026, and execution on path to profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gitlab Inc
GitLab Inc operates on an all-remote model. The company is a technology company whose primary offering is GitLab, a complete DevOps platform delivered as a single application. GitLab is used by a wide range of organizations. The company also provides related training and professional services. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. The principal markets for GitLab are currently located in the United States, Europe, and Asia Pacific. The company is focused on accelerating innovation and broadening the distribution of its platform to companies across the world.
Read more on GTLB →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
